Clinical Trial Update: Safety Study of TXA127 to Elevate CD4+ T-Lymphocyte Counts in HIV-Infected Patients on Stable HAART Therapy [Phase 1]

View source ↗

Summary

The HIV study NCT00757250 evaluating TXA127 to raise CD4+ T-cell counts in patients on HAART has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• TXA127

Snippet

Sponsor: US Biotest, Inc. | Conditions: HIV Infections | Phase 1 | Status: TERMINATED